AI-generated analysis. Always verify with the original filing.
Enzon Pharmaceuticals, Inc. issued a press release on March 9, 2026, announcing an extension to the expiration date for the exchange offer. The press release is filed as Exhibit 99.1.
Event Type
Disclosure
Voluntary
Variant
8-K
Regulation FD Disclosure. On March 9, 2026, the Company issued a press release announcing an extension to the expiration date for the exchange offer (the “ Offe
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release issued by Enzon Pharmaceuticals, Inc., dated March 9, 2026 (incorporated